Staged surgical treatment of complicated initial cataract in patients with advanced proliferative diabetic retinopathy.

IF 1.8 4区 医学 Q2 OPHTHALMOLOGY
International journal of ophthalmology Pub Date : 2025-10-18 eCollection Date: 2025-01-01 DOI:10.18240/ijo.2025.10.10
Karina I Konovalova, Michael M Shishkin, Rinat R Faizrakhmanov, Dilara B Babaeva
{"title":"Staged surgical treatment of complicated initial cataract in patients with advanced proliferative diabetic retinopathy.","authors":"Karina I Konovalova, Michael M Shishkin, Rinat R Faizrakhmanov, Dilara B Babaeva","doi":"10.18240/ijo.2025.10.10","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy of second-stage phacoemulsification (PE) of complicated initial cataract after vitreoretinal surgery (VRS) in patients with advanced proliferative diabetic retinopathy (PDR).</p><p><strong>Methods: </strong>Totally 216 patients with PDR and complicated initial cataract who underwent surgery were included. These patients were divided into four groups according to their management. In the 1<sup>st</sup> group patients were subjected to a two-step surgical procedure: VRS with silicone oil tamponade was performed as the first step, followed by the second step, PE+intraocular lens (IOL) implantation+silicone oil removal. In the 2<sup>nd</sup> group PE was performed simultaneously with VRS and silicone oil tamponade. The second step differed in the removal of silicone oil from the vitreous cavity. Patients Ia (<i>n</i>=17) and IIa (<i>n</i>=17) subgroups had their tear liquid samples being examined before surgery and on the 2<sup>nd</sup> day after the 1<sup>st</sup> phase. In subgroups Ib and IIb, an angiogenesis inhibitor was implanted 10-14d before VRS at a dose of 0.5 mg once. In the 3<sup>rd</sup> group patients were subjected to a two-step surgical procedure: VRS with gas tamponade performed as the 1<sup>st</sup> step in their treatment; followed by the 2<sup>nd</sup> step, PE and the IOL implantation. In the 4<sup>th</sup> group PE performed simultaneously with VRS with gas tamponade.</p><p><strong>Results: </strong>Patients in subgroup Ia and group III had better functional results than those in subgroup IIa and group IV, respectively (<i>P</i><0.001). More marked inflammatory response (2-3 points) was statistically significant in patients of the IIa subgroup (<i>P</i><0.001) and group IV (<i>P</i><0.001) in comparison with the patients in the Ia and group III respectively. The IIa subgroup (<i>n</i>=9; 14.5%) showed higher incidence of neovascular glaucoma (NVG) than the Ia (<i>n</i>=2; 3.2%), <i>P</i>=0.027. There also was a higher rate of NVG in group IV (<i>n</i>=6; 19.3%) compared to group III (<i>n</i>=1; 3.1%), <i>P</i>=0.04. Subgroup IIa revealed a 2 to 2.5 times higher concentration of interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), and inter-cellular adhesion molecule 1 (ICAM-1) compared to subgroup Ia.</p><p><strong>Conclusion: </strong>PE of initial cataract at the second stage after VRS in patients with advanced PDR provides a sparing approach to surgical treatment in this category of patients and allows to improve anatomical and functional results of VRS. In addition, it contributes to reduction of number and severity of postoperative complications.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 10","pages":"1888-1893"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454019/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.10.10","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To evaluate the efficacy of second-stage phacoemulsification (PE) of complicated initial cataract after vitreoretinal surgery (VRS) in patients with advanced proliferative diabetic retinopathy (PDR).

Methods: Totally 216 patients with PDR and complicated initial cataract who underwent surgery were included. These patients were divided into four groups according to their management. In the 1st group patients were subjected to a two-step surgical procedure: VRS with silicone oil tamponade was performed as the first step, followed by the second step, PE+intraocular lens (IOL) implantation+silicone oil removal. In the 2nd group PE was performed simultaneously with VRS and silicone oil tamponade. The second step differed in the removal of silicone oil from the vitreous cavity. Patients Ia (n=17) and IIa (n=17) subgroups had their tear liquid samples being examined before surgery and on the 2nd day after the 1st phase. In subgroups Ib and IIb, an angiogenesis inhibitor was implanted 10-14d before VRS at a dose of 0.5 mg once. In the 3rd group patients were subjected to a two-step surgical procedure: VRS with gas tamponade performed as the 1st step in their treatment; followed by the 2nd step, PE and the IOL implantation. In the 4th group PE performed simultaneously with VRS with gas tamponade.

Results: Patients in subgroup Ia and group III had better functional results than those in subgroup IIa and group IV, respectively (P<0.001). More marked inflammatory response (2-3 points) was statistically significant in patients of the IIa subgroup (P<0.001) and group IV (P<0.001) in comparison with the patients in the Ia and group III respectively. The IIa subgroup (n=9; 14.5%) showed higher incidence of neovascular glaucoma (NVG) than the Ia (n=2; 3.2%), P=0.027. There also was a higher rate of NVG in group IV (n=6; 19.3%) compared to group III (n=1; 3.1%), P=0.04. Subgroup IIa revealed a 2 to 2.5 times higher concentration of interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), and inter-cellular adhesion molecule 1 (ICAM-1) compared to subgroup Ia.

Conclusion: PE of initial cataract at the second stage after VRS in patients with advanced PDR provides a sparing approach to surgical treatment in this category of patients and allows to improve anatomical and functional results of VRS. In addition, it contributes to reduction of number and severity of postoperative complications.

晚期增殖性糖尿病视网膜病变并发首发白内障的分期手术治疗。
目的:评价晚期增殖性糖尿病视网膜病变(PDR)患者玻璃体视网膜手术(VRS)后并发首发白内障二期超声乳化术(PE)的疗效。方法:216例PDR合并合并首发白内障患者行手术治疗。根据治疗方法将患者分为四组。第一组患者行两步手术:第一步行VRS +硅油填塞,第二步行PE+人工晶状体植入术+硅油去除术。第二组PE与VRS和硅油填塞同时进行。第二步的不同之处在于从玻璃体腔中去除硅油。Ia (n=17)和IIa (n=17)亚组患者在手术前和第一期术后第2天检测泪液样本。在Ib和IIb亚组中,血管生成抑制剂在VRS前10-14d植入,剂量为0.5 mg,一次。第三组患者接受两步手术:第一步为VRS加气体填塞;第二步,人工晶状体和人工晶体植入术。第四组PE术与VRS术同时进行,并进行气体填塞。结果:Ia亚组和III亚组患者的功能效果分别好于IIa亚组和IV亚组(PPPn=9; 14.5%),新生血管性青光眼(NVG)发生率高于Ia亚组(n=2; 3.2%), P=0.027。IV组NVG发生率(n=6; 19.3%)高于III组(n=1; 3.1%), P=0.04。IIa亚组白细胞介素8 (IL-8)、单核细胞趋化蛋白1 (MCP-1)和细胞间粘附分子1 (ICAM-1)的浓度比Ia亚组高2 ~ 2.5倍。结论:晚期PDR患者VRS后二期初始性白内障的PE为该类患者的手术治疗提供了一种保守的方法,可以改善VRS的解剖和功能结果。此外,它有助于减少术后并发症的数量和严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
7.10%
发文量
3141
审稿时长
4-8 weeks
期刊介绍: · International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online). This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed, PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166. IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO); Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President, Chinese Academy of Engineering. International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of AAO/PAAO) et al. Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society). Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press). Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics). Associate Editors-in-Chief include: Prof. Ning-Li Wang (President Elect of APAO); Prof. Ke Yao (President of Chinese Ophthalmological Society) ; Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ; Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA); Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society); Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA); Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA). IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles, both basic and clinical papers. Instruction is Welcome Contribution is Welcome Citation is Welcome Cooperation organization International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信